CARLSBAD, Calif., April 24, 2018 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will
host a live webcast on Friday, May 4
at 11:30 a.m. Eastern Time to discuss
its first quarter 2018 financial results and report on pipeline and
business progress.
Interested parties may listen to the call by dialing
877-443-5662 or access the webcast at www.ionispharma.com. A
webcast replay will be available for a limited time at the same
address.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases. Using
its proprietary antisense technology, Ionis has created a large
pipeline of first-in-class or best-in-class drugs, with over 40
drugs in development. SPINRAZA® (nusinersen) has been
approved in global markets for the treatment of spinal muscular
atrophy (SMA). Biogen is responsible for commercializing SPINRAZA.
Inotersen and volanesorsen are two antisense drugs that Ionis
discovered and successfully advanced through Phase 3 studies.
Inotersen is under regulatory review for marketing approval in the
U.S. and EU for the treatment of patients with hereditary ATTR
amyloidosis. Volanesorsen is under regulatory review for marketing
approval in the U.S., EU and Canada for the treatment of patients with
familial chylomicronemia syndrome, or FCS. Volanesorsen is also in
a Phase 3 study in patients with familial partial lipodystrophy, or
FPL. Akcea, an affiliate of Ionis focused on developing and
commercializing drugs to treat patients with serious and rare
diseases, will commercialize inotersen and volanesorsen, if
approved. Ionis' patents provide strong and extensive protection
for its drugs and technology. Additional information about Ionis is
available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' business and the therapeutic and commercial
potential of Ionis' technologies and products in development,
including SPINRAZA, inotersen and volanesorsen. Any statement
describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Ionis' forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Ionis'
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Ionis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended December 31, 2017, which is on file with the SEC.
Copies of this and other documents are available from the
Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc. SPINRAZA® is a registered trademark of Biogen.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-first-quarter-2018-financial-results-webcast-300634834.html
SOURCE Ionis Pharmaceuticals, Inc.